The combination of JSBC and irbesartan could also effectively reduce endothelin-1 (ET-1), IL-6, TNF-α levels, and increase the expression of NO to improve vascular endothelial function and alleviate micro-inflammatory state in patients with DKD (Wu et al., 2019). The gene discussed is IL6; the disease is diabetic kidney disease.